UCB, Amgen refile osteoporosis drug Evenity
UCB and Amgen have brought their bone-boosting drug Evenity back to US regulators for review, following an initial rejection in July last year.
Read More
Tag: fracture
Trial to test fracture prevention combo in brittle bone patients
The National Institute for Health Research Efficacy and Mechanism Evaluation (EME) Programme is funding a new £1.5 million trial testing a combination of therapies to prevent rapture in patients with brittle bone disease.
Read More
- European life sciences coalition launched to boost investment ecosystem
- 99mtc‑maraciclatide granted fast track status for ILD imaging
- Bioxytran reports rapid viral clearance in phase 2 trial
- Thx Pharma and Biocodex sign rare disease licensing deal
- AstraZeneca bladder cancer therapy wins NICE backing
